Series B preferred stock cash dividend 84,520 85,240
Net loss attributable to
common stockholders $(840,633) $(1,009,753)
Basic and diluted net loss
per common share $(0.04) $(0.04)
Weighted average number of
common shares outstanding
basic and diluted 23,533,785 23,246,067
VirtualScopics, Inc. and Subsidiary
Condensed Consolidated Balance Sheets
March 31, December 31,
2009 2008
Assets (unaudited)
Current assets
Cash and cash equivalents $3,137,405 $3,143,904
Accounts receivable 1,189,828 1,021,110
Prepaid expenses and other current
assets 306,792 263,297
Total current assets 4,634,025 4,428,311
Patents, net 1,898,431 1,920,446
Property and equipment, net 368,079 355,479
Other assets 125,905 156,788
Total assets $7,026,440 $6,861,024
Liabilities and Stockholders' Equity
Current liabilities
Accounts payable and accrued expenses $691,412 $659,009
Accrued payroll 310,104 554,425
Unearned revenue 740,557 291,594
Derivative liability 820,317 -
Total current liabilities 2,562,390 1,505,028
Stockholders' Equity
Convertible preferred stock,
'/>"/>SOURCE Virtual Scopics, LLC Copyright©2009 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related medicine news :1.
VirtualScopics Announces $4.35 Million Private Placement2.
VirtualScopics Backlog Exceeds a Record $20 Million3.
VirtualScopics Receives NASDAQ Delisting Notice; Company Files Appeal to Stay Delisting4.
VirtualScopics Reports Second Quarter 2008 Results5.
VirtualScopics Schedules Third Quarter 2008 Earnings Announcement6.
VirtualScopics to Present at Two Upcoming Investor Conferences7.
VirtualScopics Reports Record Third Quarter 2008 Revenue and Gross Profit8.
VirtualScopics Backlog Rises to a Record $27 Million9.
VirtualScopics to Present at 11th Annual BIO CEO & Investor Conference10.
VirtualScopics Receives Further Extension to Regain Compliance With Nasdaq11.
VirtualScopics Scientists to Present at International Society for Magnetic Resonance in Medicine 17th Scientific Meeting and Exhibition